Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 8/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876593 | 0.82 | TDP1 (0.60) | TDP1VCAM1TSHRMAPK1PKM | |
| SCHEMBL944514 | 0.82 | TDP1 (0.44) | TDP1VCAM1TSHRMAPK1ATM | |
| SCHEMBL8095455 | 0.81 | HCAR3 (0.45) | TDP1TSHRMAPK1ATMALDH1A1 | |
| SCHEMBL31257496 | 0.81 | KMT2A (0.42) | TDP1TSHRATMALDH1A1LMNA | |
| SCHEMBL25592517 | 0.81 | TDP1 (0.48) | TDP1VCAM1TSHRMAPK1PKM | |
| SCHEMBL25339286 | 0.79 | ALDH1A1 (0.39) | TDP1TSHRATMALDH1A1LMNA | |
| SCHEMBL30273906 | 0.79 | ALDH1A1 (0.39) | TDP1TSHRATMALDH1A1LMNA | |
| SCHEMBL25220217 | 0.78 | TDP1 (0.42) | TDP1VCAM1TSHRMAPK1ALDH1A1 | |
| SCHEMBL8013048 | 0.77 | TDP1 (0.57) | TDP1VCAM1TSHRMAPK1ATM | |
| SCHEMBL30490230 | 0.77 | TDP1 (0.57) | TDP1VCAM1TSHRMAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | TDP1 2063/4885VCAM1 1176/4885TSHR 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.